Skip to main navigation
Prelude Therapeutics
  • About
    • Overview
    • Leadership
    • Board of Directors
  • Science
    • Overview
    • Pipeline
    • CDK9
    • MCL1
    • CDK4/6
    • SMARCA2
    • Discovery Engine
    • Publications
  • Clinical Trials
    • Overview
    • PRT2527 Trials
    • PRT1419 Trials
    • PRT3645 Trials
    • PRT3789 Trials
  • Investors
    • Overview
    • News & Events
      • News Releases
      • Events & Presentations
    • Financials
      • SEC Filings
      • Quarterly Results
    • Stock Information
      • Stock Quotes & Charts
      • Analysts
    • Governance
      • Governance Documents
      • Leadership
      • Committee Composition
    • Investor Resources
      • Investor FAQ's
      • Contact IR
      • Email Alerts
  • News
  • Life at Prelude
    • Overview
    • Open Positions
  • Contact

SEC Filing Details

We are focused on the rapid design and development of new medicines based on breakthroughs in cancer research.
  • About
    • Overview
    • Leadership
    • Board of Directors
  • Science
    • Overview
    • Pipeline
    • CDK9
    • MCL1
    • CDK4/6
    • SMARCA2
    • Discovery Engine
    • Publications
  • Clinical Trials
    • Overview
    • PRT2527 Trials
    • PRT1419 Trials
    • PRT3645 Trials
    • PRT3789 Trials
  • Investors
    • Overview
    • News & Events
      • News Releases
      • Events & Presentations
    • Financials
      • SEC Filings
      • Quarterly Results
    • Stock Information
      • Stock Quotes & Charts
      • Analysts
    • Governance
      • Governance Documents
      • Leadership
      • Committee Composition
    • Investor Resources
      • Investor FAQ's
      • Contact IR
      • Email Alerts
  • News
  • Life at Prelude
    • Overview
    • Open Positions
  • Contact

Document Details

Form
10-K
Filing Date
March 15, 2023
Document Date
December 31, 2022
Form Description
Annual report which provides a comprehensive overview of the company for the past year
Filing Group
Annual Filings
Company
Prelude Therapeutics
Issuer
PRELUDE THERAPEUTICS INC

Filing Formats

iXBRL
View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
XML - XBRL INSTANCE DOCUMENT
Print Page
RSS Feeds
Email Alerts
Search
preludetx.com

© Prelude Therapeutics
200 Powder Mill Road
Wilmington, DE 19803
(302) 467-1280

  • About
  • Science
  • Clinical Trials
  • Investors
  • News
  • Life at Prelude
  • Contact
visit our Twitter page visit our LinkedIn page Terms of Use Privacy Policy
logo
  • About
    • Overview
    • Leadership
    • Board of Directors
  • Science
    • Overview
    • Pipeline
    • CDK9
    • MCL1
    • CDK4/6
    • SMARCA2
    • Discovery Engine
    • Publications
  • Clinical Trials
    • Overview
    • PRT2527 Trials
    • PRT1419 Trials
    • PRT3645 Trials
    • PRT3789 Trials
  • Investors
    • Overview
    • News & Events
      • News Releases
      • Events & Presentations
    • Financials
      • SEC Filings
      • Quarterly Results
    • Stock Information
      • Stock Quotes & Charts
      • Analysts
    • Governance
      • Governance Documents
      • Leadership
      • Committee Composition
    • Investor Resources
      • Investor FAQ's
      • Contact IR
      • Email Alerts
  • News
  • Life at Prelude
    • Overview
    • Open Positions
  • Contact